includes the risk of identification and treatment of artifacts that do not impact offspring health, thus exposing both fetus and mother to long-term side effects of dexamethasone; this risk must be balanced against the potentially devastating impact of CHB. All discussions should acknowledge the limited data and consider the patient's values and preferences. We conditionally recommend treating all women who are positive for anti-Ro/SSA and/or anti-La/SSB antibodies with HCQ during pregnancy.